Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Azitra, Inc. (AZTR)
USD0.14
+0.01 (+4.97%)
US AMEX Healthcare Biotechnology
Address
21 Business Park Drive 6405
Branford, CT, US
Branford, CT, US
CEO
Francisco D. Salva
Website
azitrainc.com
IPO
2023-06-20
CIK 1701478 ISIN US05479L3024
Description
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.14
+0.01 (+4.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
-1.28
Float Shares
10.19M
Free Float %
94.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50% | -8.52% | +1.78% | +8.51% | -37.29% | -18.13% | -88.34% | -99.98% | -99.98% | -99.98% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.14
DCF (Unlevered)
337.69
+249,856.8%
DCF (Levered)
337.74
+249,894.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-8.52
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-532.3% Q1'26: -623.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-0.5% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+758.7% Q1'26: +684.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-40.25× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
686.0K
est: 572.7K (+19.8%)
|
7.50M
est: 8.0K (+93,650.0%)
|
—
est: 3.00M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
20.27M
20.27M – 20.27M
|
20.68M
20.68M – 20.68M
+2.0% YoY
|
93.02M
93.02M – 93.02M
+349.9% YoY
|
| EBITDA |
-10.67M
est: -343.6K (-3,006.1%)
|
-8.50M
est: -4.8K (-176,943.0%)
|
-10.49M
est: -1.80M (-482.6%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
-12.16M
-12.16M – -12.16M
|
-12.41M
-12.41M – -12.41M
-2.0% YoY
|
-55.81M
-55.81M – -55.81M
-349.9% YoY
|
| EBIT |
-11.10M
est: -343.6K (-3,129.9%)
|
-8.95M
est: -4.8K (-186,281.3%)
|
-10.94M
est: -1.80M (-507.7%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
-12.16M
-12.16M – -12.16M
|
-12.41M
-12.41M – -12.41M
-2.0% YoY
|
-55.81M
-55.81M – -55.81M
-349.9% YoY
|
| Net Income |
-11.28M
est: -154.91M (+92.7%)
|
-8.97M
est: -66.54M (+86.5%)
|
-10.96M
est: -12.09M (+9.4%)
|
-2.00M
-2.00M – -2.00M
+83.5% YoY
|
-1.56M
-1.56M – -1.56M
+22.0% YoY
|
-438.6K
-438.6K – -438.6K
+71.9% YoY
|
-243.7K
-243.7K – -243.7K
+44.4% YoY
|
584.8K
584.8K – 584.8K
+340.0% YoY
|
| SGA |
4.49M
est: 102.19M (-95.6%)
|
6.27B
est: 1.43M (+439,077.1%)
|
6.13B
est: 535.31M (+1,045.2%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
3.62B
3.62B – 3.62B
|
3.69B
3.69B – 3.69B
+2.0% YoY
|
16.60B
16.60B – 16.60B
+349.9% YoY
|
| EPS |
-7.34
est: -31.79 (+76.9%)
|
-0.36
est: -13.65 (+97.4%)
|
-2.25
est: -2.48 (+9.3%)
|
-0.41
-0.41 – -0.41
+83.5% YoY
|
-0.32
-0.32 – -0.32
+22.0% YoY
|
-0.09
-0.09 – -0.09
+71.9% YoY
|
-0.05
-0.05 – -0.05
+44.4% YoY
|
0.12
0.12 – 0.12
+340.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-90.47M
OE per share TTM
-20.59
Owner's Yield
-8,036.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11,279.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
3
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AARON GLENN LOUIS FLETCHER | 6.96M | 56.90% | 162.0K | 6.80M | 162.0K | 10.00 | IN | UNITED STATES | 2023-07-03 | ↗ |
| 2 | LESLIE WAYNE KREIS, JR. | 6.89M | 56.30% | 91.0K | 6.80M | 91.0K | 10.00 | IN | UNITED STATES | 2023-07-03 | ↗ |
| 3 | BIOS ADVISORS GP, LLC | 6.80M | 55.60% | — | 6.80M | — | 10.00 | OO | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 4 | BIOS CAPITAL MANAGEMENT, LP | 6.80M | 55.60% | — | 6.80M | — | 10.00 | PN | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 5 | CAVU ADVISORS, LLC | 6.80M | 55.60% | — | 6.80M | — | 10.00 | OO | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 6 | CAVU MANAGEMENT, LP | 6.80M | 55.60% | — | 6.80M | — | 10.00 | PN | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 7 | BIOS EQUITY PARTNERS III, LP | 3.48M | 28.80% | — | 3.48M | — | 10.00 | PN | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 8 | BIOS FUND III QP, LP | 2.64M | 21.90% | — | 2.64M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 9 | BIOS EQUITY PARTNERS II, LP | 2.06M | 16.80% | — | 2.06M | — | 10.00 | PN | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 10 | Laurence W. Lytton | 1.67M | 11.00% | 1.67M | — | 1.67M | — | IN | USA | 2024-02-27 | ↗ |
| 11 | Alpha 18 Inc. | 1.50M | 5.20% | — | — | — | — | CO | Delaware | 2024-02-26 | ↗ |
| 12 | Noam Dunsky | 1.50M | 5.20% | — | — | — | — | IN | Delaware | 2024-02-26 | ↗ |
| 13 | Bayer Aktiengesellschaft | 1.31M | 10.80% | — | — | — | 1.31M | HC, CO | Delaware | 2024-02-12 | ↗ |
| 14 | Bayer HealthCare LLC | 1.31M | 10.80% | — | — | — | 1.31M | CO | Delaware | 2024-02-12 | ↗ |
| 15 | Bayer US Holding LP | 1.31M | 10.80% | — | — | — | 1.31M | PN | Delaware | 2024-02-12 | ↗ |
| 16 | Bayer World Investments B.V. | 1.31M | 10.80% | — | — | — | 1.31M | CO | Delaware | 2024-02-12 | ↗ |
| 17 | BIOS EQUITY PARTNERS, LP | 1.27M | 10.50% | — | 1.27M | — | 10.00 | PN | TEXAS, UNITED STATES | 2023-07-03 | ↗ |
| 18 | BIOS FUND II QP, LP | 1.10M | 9.00% | — | 1.10M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 19 | BIOS FUND I, LP | 799.5K | 6.60% | — | 799.5K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 20 | L1 Capital Global Opportunities Master Fund, Ltd. | 776.4K | 9.99% | 776.4K | — | — | — | FI | Cayman Islands | 2024-07-29 | ↗ |
| 21 | CVI Investments, Inc. | 610.0K | 8.00% | — | — | — | 610.0K | CO | — | 2024-08-01 | ↗ |
| 22 | Heights Capital Management, Inc. | 610.0K | 8.00% | — | — | — | 610.0K | CO | — | 2024-08-01 | ↗ |
| 23 | BIOS AZITRA CO-INVEST I, LP | 475.9K | 3.90% | — | 475.9K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 24 | BIOS FUND I QP, LP | 467.6K | 3.90% | — | 467.6K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 25 | BIOS FUND III NT, LP | 426.9K | 3.50% | — | 426.9K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 26 | BIOS FUND III, LP | 404.8K | 3.30% | — | 404.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 27 | BIOS FUND II, LP | 336.0K | 2.80% | — | 336.0K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
| 28 | BIOS FUND II NT, LP | 146.9K | 1.20% | — | 146.9K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2023-07-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
320.7K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+320,703
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Whitfill Travis | Director / Officer | A-Award | A | Stock Options (Right To Buy) | 64,300 | 0.21 | 13.7K | 64,300 | D | ↗ |
| 2026-04-20 | Staskey Norm | Officer | A-Award | A | Stock Options (Right To Buy) | 35,524 | 0.21 | 7.6K | 35,524 | D | ↗ |
| 2026-04-20 | Salva Francisco D. | Director / Officer | A-Award | A | Stock Options (Right To Buy) | 220,879 | 0.21 | 47.0K | 220,879 | D | ↗ |
| 2026-03-18 | Salva Francisco D. | Director / Officer | P-Purchase | A | Series B Warrants | 4,064,050 | 0.12 | 499.9K | 4,064,050 | D | ↗ |
| 2025-12-19 | Whitfill Travis | Director / Officer | A-Award | A | Stock Options (Right To Buy) | 23,724 | 0.30 | 7.0K | 23,724 | D | ↗ |
| 2025-12-19 | Staskey Norm | Officer | A-Award | A | Stock Options (Right To Buy) | 15,015 | 0.30 | 4.5K | 15,015 | D | ↗ |
| 2025-12-19 | Schroer John R. | Director | A-Award | A | Stock Options (Right To Buy) | 3,003 | 0.30 | 891.29 | 3,003 | D | ↗ |
| 2025-12-19 | Salva Francisco D. | Director / Officer | A-Award | A | Stock Options (Right To Buy) | 59,309 | 0.30 | 17.6K | 59,309 | D | ↗ |
| 2025-12-19 | Ryan Barbara | Director | A-Award | A | Stock Options (Right To Buy) | 3,003 | 0.30 | 891.29 | 3,003 | D | ↗ |
| 2024-03-29 | Staskey Norm | Officer | P-Purchase | A | Common Stock | 47,600 | 0.21 | 10.0K | 51,100 | — | ↗ |
| 2024-02-13 | Whitfill Travis | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.30 | 4.5K | 334,500 | — | ↗ |
| 2024-02-13 | Staskey Norm | Officer | P-Purchase | A | Common Stock | 3,300 | 0.30 | 990.00 | 3,500 | — | ↗ |
| 2024-02-13 | Salva Francisco D. | Director / Officer | P-Purchase | A | Common Stock | 333,300 | 0.30 | 100.0K | 338,300 | — | ↗ |
| 2023-09-08 | Whitfill Travis | Director / Officer | A-Award | A | Stock Options (Right To Buy) | 10,000 | 2.07 | 20.7K | 103,152 | — | ↗ |
| 2023-09-08 | Staskey Norm | Officer | A-Award | A | Stock Options (Right To Buy) | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2023-09-08 | Schroer John R. | Director | A-Award | A | Stock Options (Right To Buy) | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2023-09-08 | Ryan Barbara | Director | A-Award | A | Stock Options (Right To Buy) | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2023-06-21 | Whitfill Travis | Director / Officer | A-Award | A | Common Stock | 250 | 5.00 | 1.3K | 250 | — | ↗ |
| 2023-06-21 | Salva Francisco D. | Director / Officer | A-Award | A | Common Stock | 5,000 | 5.00 | 25.0K | 5,000 | — | ↗ |
| 2023-06-21 | McClary Andrew | Director | C-Conversion | D | Unsecured convertible promissory note | 0 | 2.50 | — | 0 | — | ↗ |
| 2023-06-21 | Kreis Leslie W. | 10% Owner | C-Conversion | A | Common Stock | 834,632 | 1.10 | 918.1K | 834,632 | — | ↗ |
| 2023-06-21 | Fletcher Aaron G.L. | 10% Owner | C-Conversion | A | Common Stock | 111,720 | 1.10 | 122.9K | 111,720 | — | ↗ |
| 2023-06-21 | BAYER HEALTHCARE LLC | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 1,307,401 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Whitfill Travis | Director / Officer | — | D | Stock Option (Right to Buy) | 55,785 | 0.48 | 26.8K | 0 | — | ↗ |
| 2023-06-15 | Staskey Norm | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Schroer John R. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Salva Francisco D. | Director / Officer | — | D | Stock Option (Right to Buy) | 465,760 | 1.70 | 791.8K | 0 | — | ↗ |
| 2023-06-15 | Ryan Barbara | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | McClary Andrew | Director | — | I | Series A-1 Convertible Preferred Stock, par value $0.0001 | 248,908 | 4.83 | 1.20M | 0 | — | ↗ |
| 2023-06-15 | Kreis Leslie W. | 10% Owner | — | I | Series B Convertible Preferred Stock | 808,058 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Fletcher Aaron G.L. | 10% Owner | — | I | Convertible Notes | 0 | 0.00 | — | 509,141 | — | ↗ |
| 2023-06-15 | BAYER HEALTHCARE LLC | 10% Owner | — | D | Series B Convertible Preferred Stock | 1,307,401 | 0.00 | — | 0 | — | ↗ |
| 2019-03-29 | Kreis Leslie W. | 10% Owner | — | I | Warrants (Right to Buy) | 39,760 | 5.28 | 209.9K | 0 | — | ↗ |
| 2019-03-29 | Fletcher Aaron G.L. | 10% Owner | — | I | Warrants (Right to Buy) | 39,760 | 5.28 | 209.9K | 0 | — | ↗ |
| 2019-02-22 | McClary Andrew | Director | — | I | Warrants | 21,804 | 5.28 | 115.1K | 0 | — | ↗ |
| 2018-04-13 | Kreis Leslie W. | 10% Owner | — | I | Warrants (Right to Buy) | 13,092 | 0.48 | 6.3K | 0 | — | ↗ |
| 2018-04-13 | Fletcher Aaron G.L. | 10% Owner | — | I | Warrants (Right to Buy) | 13,092 | 0.48 | 6.3K | 0 | — | ↗ |
| 2005-03-04 | GABELLI ASSET MANAGEMENT INC ET AL | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 9,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
10.74M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Francisco D. Salva President and Chief Executive Officer | 420.0K | — | — | — | — | 7.0K | 427.0K | 0.00% | ↗ |
| 2 | 2023 | Norman Staskey Chief Financial Officer | — | — | — | 20.7K | — | 314.0K | 334.7K | 6.18% | ↗ |
| 3 | 2023 | Travis Whitfill Chief Operating Officer | 158.8K | — | — | 20.7K | — | 2.8K | 182.3K | 11.35% | ↗ |
| 4 | 2022 | Francisco D. Salva President and Chief Executive Officer | 403.8K | — | — | — | — | 202.00 | 404.0K | 0.00% | ↗ |
| 5 | 2022 | Norman Staskey Chief Financial Officer | — | — | — | — | — | 63.2K | 63.2K | 0.00% | ↗ |
| 6 | 2022 | Travis Whitfill Chief Operating Officer | — | — | — | — | — | 10.1K | 10.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-05-08 | DEF 14A | ↗ |
| 2026-04-27 | PRE 14A | ↗ |
| 2026-03-05 | DEFA14A | ↗ |
| 2026-02-06 | DEFA14A | ↗ |
| 2026-01-02 | DEF 14A | ↗ |
| 2025-12-23 | PRE 14A | ↗ |
| 2025-06-18 | DEFA14A | ↗ |
| 2025-05-29 | DEF 14A | ↗ |
| 2025-05-19 | PRE 14A | ↗ |
| 2025-01-14 | DEFA14A | ↗ |
| 2025-01-14 | DEF 14A | ↗ |
| 2025-01-03 | PRE 14A | ↗ |
| 2024-10-09 | DEF 14A | ↗ |
| 2024-06-03 | DEF 14A | ↗ |
| 2024-05-24 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Francisco D. Salva | President, Chief Executive Officer & Director | 566.6K | male |
| Norman Staskey | Chief Financial Officer & Treasurer | 493.6K | male |
| Travis Whitfill | Co-Founder, Chief Operating Officer, Secretary & Director | 485.4K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AZTR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
